ArticleNature medicine2017

Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.

Meenu Kesarwani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.